| Literature DB >> 24806725 |
Graham W Gibbs1, France Labrèche.
Abstract
OBJECTIVE AND METHODS: This review examines epidemiological evidence relating to cancers in the primary aluminum industry where most of what is known relates to Söderberg operations or to mixed Söderberg/prebake operations. RESULTS ANDEntities:
Mesh:
Substances:
Year: 2014 PMID: 24806725 PMCID: PMC4131938 DOI: 10.1097/JOM.0000000000000003
Source DB: PubMed Journal: J Occup Environ Med ISSN: 1076-2752 Impact factor: 2.162
FIGURE 1.Various types of aluminum reduction cells (pots).1
Typical Measured Exposure Levels of Benzo(a)pyrene in Aluminum Reduction Plants
| References | Plant Country (Province/State) | Department/Job/Task | Concentrations | Comments |
|---|---|---|---|---|
| Bjørseth et al | Norway | Anode plant | ND–0.3 μg/m3 | Stationary samples ( |
| Prebake plant | ND–0.05 μg/m3 | Mid-1970s | ||
| Söderberg potroom | ND–9.0 μg/m3 | |||
| Lindstedt and Sollenberg | Sweden | Söderberg plant | 1.8–5.3 μg/m3 | Stationary samples ( |
| 1968–1978 | ||||
| Tjoe Ny et al | Suriname | Söderberg plant | Geometric mean: | Personal samples ( |
| Potmen | 2.2 μg/m3 | July to August 1990 | ||
| Electrode men | 37 μg/m3 | |||
| Petry et al | Switzerland | Anode plant | 8-h time-weighted averages:0.16–4.88 μg/m3 | Personal samples, 5-d full-shift samples ( |
| Early 1990s | ||||
| Carstensen et al | Sweden | Söderberg potrooms | Time-weighted average median concentrations of particulates: | Personal, full-shift samples ( |
| 0.97 μg/m3 (range: 0.02–23.5) | End of the 1990s | |||
| Sanderson et al | Canada (Quebec and British Columbia) | Söderberg plantStud maintenance, crust breakerAnode operator, rack raiserPotroom control operator | Geometric mean concentrations:1998: 1.68 μg/m3/2002: 1.14 μg/m31998: 5.72 μg/m3/2002: 1.80 μg/m31998: 1.15 μg/m3/2002: 0.26 μg/m3 | Personal samples ( |
| Lavoué et al | Canada (Quebec) | Söderberg potrooms | Median geometric mean: 0.46 μg/m3Maximum geometric mean: 134.28 μg/m3 | One plant with the largest number of measurements ( |
ND, Not Detected.
Brief Description of Published Cohort Studies on Workers in Aluminum Reduction Plants
| References, Country (Province/State) Study Design | Department/Job/Task | Comparison Group | Follow-Up Period | Comments | Person-Years of Observation (Total Cancer Deaths or Cases) |
|---|---|---|---|---|---|
| Australia | |||||
| Sim et al, | 2 aluminum reduction plants, started in 1962 and 1986 (prebake process) 4396 men (565 women not described) | General Australian population | 1983–2002 | “Young” cohort and short period of follow-up (31% of p-y before 1991 and 24% after 1998) Some smoking data Number lost to follow-up not specified >88% of cause of death determined | 68,752 p-y(78 cancer deaths/233 new cases) |
| Canada | |||||
| Spinelli et al | 1 aluminum reduction plant (Söderberg process) 6423 workers with ≥3 yrs of employment between 1954 and 1997 | General British Columbia population | Mortality:1957–1999Incidence:1970–1999 | Little smoking data 13.6% lost to follow-up >98% of cause of death determined | 151,057 p-y(336 cancer deaths/662 new cases) |
| Gibbs et al | 4 aluminum reduction plants (A: old prebake + Söderberg; B and C: Söderberg; D: prebake) Plant A—pre-1950 (started in 1920): 5285 men working on January 1, 1950 Plant B—pre-1951 (started in 1916): 529 men working on January 1, 1951 Plant C—pre-1950 (started in 1937): 163 men working on January 1, 1950 Plant A—post-1950: 6697 men hired after January 1, 1950 Plant B—post-1951: 1082 men hired after January 1, 1951 Plant C—post-1950: 1379 men hired after January 1, 1950 Plant D (started in 1978): 568 men hired since 1978 | General Quebec population | Mortality: A: 1950–1999B: 1951–1999C: 1950–1999D: 1978–1999Incidence:1980–1999 | Large study with several cohorts Some smoking data Number lost to follow-up not specified but mentioned that vital status was ascertained for virtually all workers 97%–100% of cause of death determined | p-yA pre: 188,263.4B pre: 19,980.1C pre: 5779.8A post: 172,798.5B post: 24,324.6C post: 41,552.6D: 8476(5474 cancer deaths/>1878 new cases) |
| China | |||||
| Liu et al | 6 carbon plants and 1 potroom and carbon department of an aluminum reduction plant (process not specified) 6635 men working since January 1, 1971 (unspecified number of workers in the aluminum reduction plant) | 11,470 males in steel rolling mills | 1971–1985 | Most workers from carbon plants Individual data on smoking 1.34% lost to follow-up 100% of cause of death determined | 95,847 p-y(149 cancer deaths) |
| France | |||||
| Mur et al | 11 aluminum reduction plants (3 prebake, 2 Söderberg, others mixed processes) 6455 men employed for ≥1 yr between 1950 and 1976 | General French population | 1950–1976 | Large study with several cohorts Some smoking data Approximately 2% lost to follow-up Only 71.3% of cause of death determined | 113,671 p-y(199 cancer deaths) |
| Moulin et al | 1 aluminum reduction plant (both prebake and Söderberg processes) (originally studied in Mur et al 2133 men employed for ≥1 yr between 1950 and 1994 | Regional population | 1968–1994 | Some smoking data Exclusion of workers born outside France 9.5% lost to follow-up 94% of cause of death determined | 35,145 p-y(101 cancer deaths) |
| Italy | |||||
| Giovanazzi and D'Andrea | 1 aluminum reduction plant (mainly Söderberg) 494 men employed (212 potroom workers and a “control” group of 282 workers from other departments) | General Italian population and Trento province population | 1965–1979 | Statistically significant excess of deaths from liver cirrhosis among potroom workers Small numbers No smoking data Number lost to follow-up not specified Unspecified percentage of cause of death determined | All plant: 5306 p-y (56 cancer deaths)Potroom: 2115 (40 cancer deaths) |
| Carta et al | 1 aluminum reduction plant (prebake) 1152 men employed for ≥1 yr between 1972 and 1980 Nested case-control study: 6 cases, 72 controls | Regional population | 1972–2001 | Some smoking data No loss to follow-up 100% of cause of death determined | 29,010.8 p-y(51 cancer deaths; 6 deaths from pancreatic cancer) |
| Norway | |||||
| Andersen et al | 4 aluminum reduction plants (both prebake and Söderberg processes) 7410 men alive in 1953 and employed before 1970 for ≥18 mo | Specific county population | Mortality and incidence:1953–1979 | Large study with several cohorts No smoking data Number lost to follow-up not specified No analysis of cancer mortality | Person-years of observation not specified(unspecified number of cancer deaths, 428 new cases) |
| Rönneberg et al | 1 aluminum reduction plant (prebake process) (originally studied in Andersen et al 1137 men employed for ≥6 mo between 1922 and 1975 (plant closure) | General Norwegian population | 1953–1991 | Little smoking data 3.9% lost to follow-up No analysis of cancer mortality | 32,816 p-y552 cancer deaths, 210 new cases) |
| Rönneberg et al | 1 aluminum reduction plant (Söderberg process) (originally studied in Andersen et al Men employed for ≥6 mo 2647 short-term workers (employed for <4 yrs) 2888 production workers (≥4 yrs) 373 maintenance workers (≥4 yrs) | General Norwegian population | 1953–1993 | No smoking data 0.8% lost to follow-up | Short term: 65,976 p-y (226 new cases)Production: 71,219 p-y (339 new cases)Maintenance: 9950 p-y(41 new cases) |
| Romundstad et al | 6 aluminum reduction plants (both prebake and Söderberg processes) (5 of which were originally studied in Andersen et al 11,103 men employed for >3 yrs | General Norwegian population | 1953–1996 | Large study with several cohorts Smoking data available for three plants/six Number lost to follow-up not specified | 272,554 p-y(1503 new cases) |
| Romundstad et al | 2 aluminum reduction plants (mainly Söderberg process) (1 of them originally studied in Andersen et al 5627 men employed for >6 mo | General Norwegian population | Mortality: 1962–1995Incidence: start of employment—1995 | Smoking data available for 80% of workers for >3 yrs Number lost to follow-up not specified Unspecified percentage of cause of death determined | Mortality: 128,020 p-y (226 cancer deaths)Incidence: 139,554 p-y (425 new cases) |
| Romundstad et al | 1 aluminum reduction plant (originally Prebake, changed to the Söderberg process in 1939) (also reported in Romundstad et al 1790 men employed for >5 yrs | General Norwegian population | 1953–1995 | Some smoking data available for 75% of workers for >5 yrs Approximately 2% lost to follow-up | 36,587 p-y (286 new cases) |
| Konstantinov | As reported in Simonato No information on size of cohort, duration of follow-up, or process | Not specified | 1956–1966 | No information on size of cohort, duration of follow-up, or losses to follow-up, smoking data | Not specified |
| Björ et al | 1 aluminum reduction plant (started in 1942, Söderberg process) 2264 men (excluding office workers) employed for >6 mo between 1942 and 2000 | Three for mortality: general Swedish, Northern Swedish, and county populationsIncidence: the fourth one: seven largest municipalities in Northern Sweden | Mortality:1952–2004Incidence:1958–2005 | No smoking data Number lost to follow-up not specified, but probably very low | 70,856 p-y(170 cancer deaths, 323 new cases) |
| USAMilham | 1 aluminum reduction plant (started in 1946, prebake process) 2103 men who worked for ≥3 yrs at the plant and at least 1 yr between 1946 and 1962 and were still alive in 1962 | General US population | 1962–1976 | No smoking data Number lost to follow-up not specified 95.5% of cause of death determined No information on workers who left or died before 1962 | 44,307 p-y(98 cancer deaths) |
| Rockette and Arena | 14 aluminum reduction plants (both prebake and Söderberg processes) 21,829 men who worked for ≥5 yrs at one of the plants between 1946 and 1977 | General US population | 1946–1977 | Very large study with several cohorts No smoking data 1.2% lost to follow-up except for two plants with six and 16% missing files 97.6% of cause of death determined | Person-years of observation not specified(796 cancer deaths) |
BC, British Columbia; p-y, person-years of observation; QC, Quebec; WA, Washington State.
Cohort Studies* That Have Reported Significant and Nonsignificant Excesses (Risk Estimate of 110 or More) of Malignant Tumors in Aluminum Workers in Various Countries
| Mortality | Incidence | |||
|---|---|---|---|---|
| Malignant Tumor Site | Statistically Significant Excess | Nonstatistically Significant Excess | Statistically Significant Excess | Nonstatistically Significant Excess |
| Buccal cavity and pharynx | Spinelli et al | Spinelli et al | ||
| Gibbs et al | Gibbs and Sévigny | |||
| Lip | Romundstad et al | |||
| Spinelli et al | ||||
| Esophagus | Liu et al | Gibbs and Sévigny | Björ et al | Gibbs and Sévigny |
| Stomach | Konstantinov et al | Giovanazzi and D'Andrea | Spinelli et al | Romundstad et al |
| Liu et al | ||||
| Spinelli et al | ||||
| Gibbs and Sévigny | ||||
| Small intestine | Gibbs and Sévigny | |||
| Colon | Romundstad et al | |||
| Rectum and rectosigmoid junction or rectum | Gibbs et al | Gibbs and Sévigny | Romundstad et al | |
| Gibbs and Sévigny | ||||
| Peritoneum | Gibbs and Sévigny | |||
| Liver | Liu et al | Milham | Rommunstad et al | |
| Mur et al | Gibbs and Sévigny | |||
| Pancreas | Rockette and Arena | Milham | Romundstad et al | Spinelli et al |
| Carta et al | Rockette and Arena | Gibbs and Sévigny | ||
| Gibbs et al | Mur et al | |||
| Moulin et al | ||||
| Spinelli et al | ||||
| Gibbs and Sévigny | ||||
| Nose and sinuses | Spinelli et al | Romundstad et al | ||
| Larynx | Gibbs et al | Gibbs and Sévigny | Gibbs and Sévigny | Romundstad |
| Moulin et al | Sim et al | |||
| Lung/bronchus, trachea, and lung | Konstantinov et al | Giovanazzi and D'Andrea | Gibbs and Sévigny | Romundstad |
| Liu et al | Rockette and Arena | Björ et al | Spinelli et al | |
| Gibbs et al | Mur et al | Sim et al | ||
| Gibbs and Sévigny | Sim et al | |||
| Pleura | Spinelli et al | Spinelli et al | ||
| Gibbs and Sévigny | ||||
| Pleural mesothelioma | Sim et al | Sim et al | ||
| Respiratory tract | Milham | Sim et al | ||
| Bone | Mur et al | Gibbs and Sévigny | ||
| Skin | Konstantinov et al | Mur et al | ||
| Breast in males | Mur et al | Spinelli et al | ||
| Prostate | Sim et al | Milham | Romundstad et al | |
| Gibbs et al | Gibbs and Sévigny | |||
| Gibbs and Sévigny | ||||
| Testis | Milham | Romundstad et al | ||
| Spinelli et al | ||||
| Sim et al | ||||
| Penis | Rommundstad et al | |||
| Bladder | Gibbs et al | Rockette and Arena | Romundstad et al | Romundstad et al |
| Mur et al | Spinelli et al | Sim et al | ||
| Moulin et al | Gibbs and Sévigny | |||
| Spinelli et al | ||||
| Gibbs and Sévigny | ||||
| Sim et al | ||||
| Kidney | Milham | Rommundstad et al | Romundstad et al | |
| Rockette and Arena | Sim et al | Gibbs and Sévigny | ||
| Gibbs et al | ||||
| Sim et al | ||||
| Urinary tract | Sim et al | Björ et al | ||
| Brain/central nervous system (malignant tumors) | Milham | Björ et al | Spinelli et al | |
| Pituitary adenomas | Cullen et al | |||
| Thyroid | Romundstad et al | |||
| Head and neck | Björ et al | |||
| Lymphosarcoma and reticulosarcoma | Milham | Rockette and Arena | ||
| Hodgkin disease | Milham | Romundstad et al | ||
| Gibbs et al | Gibbs and Sévigny | |||
| Non-Hodgkin lymphoma | Spinelli et al | Gibbs and Sévigny | ||
| Gibbs et al | ||||
| Gibbs and Sévigny | ||||
| Multiple myeloma | Mur et al | Romundstad et al | ||
| Gibbs et al | ||||
| Gibbs and Sévigny | ||||
| Other lymphatic cancers | Rockette and Arena | |||
| Gibbs et al | ||||
| Leukemia | Milham | Romundstad et al | ||
| Rockette and Arena | Gibbs and Sévigny | |||
| Mur et al | ||||
| Gibbs and Sévigny | ||||
| Lymphatic and hemopoietic cancers | Milham | Rockette and Arena | Gibbs and Sévigny | |
*Not all authors are reported as later articles incorporated the same cohorts. Some of the excesses in this table did not show relationships with employment duration or exposure levels.
†Production, potroom, or maintenance workers.
‡Maintenance only, not production.
[P], prebake; [S], Söderberg process; [S+P], both Söderberg and prebake processes; [U], unspecified reduction process.
Summary of the Available Evidence* of a Causal Relationship Between Work in Aluminum Production and Selected Cancer Sites
| Cancer Sites | Strength of Association | Strength (More Than 100,000 Person-Years) | Any SS Increase | Consistency | Exposure Gradient | Comments | Force of Evidence |
|---|---|---|---|---|---|---|---|
| Buccal cavity and pharynx | M: 0.13–2.38; I: 0.79–3.16 | M: 0.66–2.38; I: 0.0.79–3.16 | No | Decreased risk found in most studies | Little evidence (in one study, among smokers) | Mostly decreased risk, little evidence of exposure–response, but the effect of potential confounders cannot be ruled out | – |
| Esophagus | M: 0.54–5.46; I: 0.6–2.58 | M: 0.54–1.32; I: 0.6–2.56 | Yes: I(1), M(1) | No (increased in China and Sweden) | No evidence (no: one study) | Mostly decreased risk, no evidence of exposure–response, and the effect of potential confounders cannot be ruled out | – |
| Stomach | M: 0.74–2.3; I: 0.65–4.04 | M: 1.0–1.48; I: 1.0–4.04 | Yes: I(3), M(2); EG with B(a)P(2) | No (variable results) | Some evidence (yes: two mortalities, one incidence; no: one mortality, one incidence) | Moderate increase in risk, inconsistent results, some evidence of exposure– response after adjustment for smoking, but the effect of potential confounders cannot totally be ruled out | + |
| Rectum and rectosigmoid junction or rectum | M: 0.46–1.30; I: 0.65–1.452 | M: 0.74–1.304; I: 0.97–1.452 | No | No increased risk in most studies | Little evidence (yes: one study) | Mostly no increase in risk, little evidence of exposure–response, but the effect of potential confounders cannot be ruled out. Few reports | – |
| Pancreas | M: 0.92–1.49; I: 0.9–2.59 | M: 1.08–1.49; I: 0.9–2.59 | Yes: I(2), M(2); EG with PAHs(2) | Increased risk in most studies | Some evidence (yes: three to four studies; no: one study) | Moderate to high increase in risk, some consistency between studies, some evidence of exposure–response in a few plants, but the effect of potential confounders cannot be ruled out | ++ |
| Larynx | M: 0.907–1.57; I: 0.79–5.67 | M: 0.907–1.57; I: 0.79–5.67 | Yes: I(1) | No increased risk in most studies | No evidence (no: one study) | Moderate to high increase in risk, studies generally negative, no evidence of exposure–response, but the effect of potential confounders cannot be ruled out | – |
| Lung/bronchus, trachea, and lung | M: 0.63–4.3; I: 1.0–2.65 | M: 1.07–1.36; I: 1.0–2.12 | Yes: I(2), M(2); EG with B(a)P(2) | Increased risk found in all but two studies | Very good evidence (yes, several studies; also for smoking-adjusted risks) | Moderate increase in risk, studies generally positive, very good evidence of exposure–response, after adjustment for smoking | +++ |
| Pleura, including mesothelioma | M: 1.98–4.36; I: 1.37–3.02 | M: 1.98; I: 1.37–3.02 | Yes: I(1), M(1) | Risk not reported in most studies | Insufficient evidence | Rare cancer. Risk appears to be probably associated with use of asbestos. Few reports | – |
| Bone | M: 2.04; I: 1.36 | M: NA; I: 1.36 | No | Insufficient reports | Insufficient evidence | Very rare cancer. Small increase, no evidence of exposure–response. Very few reports | ? |
| Skin melanoma | M: NA; I: 0.35–1.66 | M: NA; I: 0.5–0.80 | No | Decreased risk found in most studies | No evidence | Mostly decreased risk, no evidence of exposure–response, no adjustment for potential confounders | – |
| Skin nonmelanoma | M: NA; I: 0.8–1.05 | M: NA; I: 0.8 | No | Decreased risk found in most studies | No evidence | Mostly decreased risk, no evidence of exposure–response, no adjustment for potential confounders | – |
| Prostate | M: 0.63–2.11; I: 0.48–1.55 | M: 0.70–0.93; I: 0.96–1.45 | Yes: I(1), M(1) | Decreased risk found in most mortality studies. Increased risk in many incidence studies | Little evidence (yes: one mortality study; no: two incidence studies | Some increased incidence risks, decreased risk in most mortality studies, little evidence of exposure–response | – |
| Testis | M: 0.76–7.07; I: 0.74–1.57 | M: NA; I: 0.8–1.12 | No | No (variable results) | No evidence (no: one study) | Small increase in risk, no evidence of exposure–response, no adjustment for potential confounders. Very few reports | – |
| Bladder | M: 0.65–2.24; I: 0.78–4.9 | M: 0.85–2.24; I: 1.3–4.9 | Yes: I(3), M(1); EG with B(a)P(4) | Increased risk in most studies | Very good evidence (yes: three to four studies; no: two studies) | Small to high increased risk, studies generally positive, very good evidence of exposure–response, after adjustment for smoking | +++ |
| Kidney | M: 0.49–2.09; I: 0.74–1.99 | M: 0.49–1.06; I: 0.96–1.96 | Yes: I(2); EG with B(a)P(2) | Increased risk in several studies | Some evidence (yes: three studies; no: two studies) | Small to moderate increase in risk (incidence), several positive studies, some evidence of exposure–response | + |
| Brain/central nervous system | M: 0.54–2.13; I: 0.62–1.90 | M: 0.967–2.13; I: 0.90–1.48 | Yes: I(1) | Increased risk in several studies | Little evidence (borderline yes: one study; no: one study) | Small to high increase in risk, several positive studies, little evidence of exposure–response | ± |
| Lymphosarcoma and reticulosarcoma | M: 1.16–1.75; I: NA | M: NA; I: NA | Yes: M(1) | Insufficient reports (two mortality studies) | Insufficient evidence | Small to moderate increase in risk. Very few reports | ? |
| Hodgkin disease | M: 0.24–3.97; I: 0.36–1.96 | M: 0.3–1.16; I: 0.49–1.93 | No | Increased risk in a few studies | Insufficient evidence | Small to moderate increase in risk, no clear evidence of exposure–response, no adjustment for potential confounders | – |
| Non-Hodgkin lymphomas | M: 0.24–1.42; I: 0.36–1.96 | M: 0.24–1.42; I: 0.90–1.55 | Yes: I(1); EG with B(a)P(1) | Increased risk in a few studies | Little evidence (yes in study); borderline (no in one study) | Small to moderate increase in risk, little evidence of exposure–response, no adjustment for potential confounders | ± |
| Multiple myeloma | M: 0.84; I: 0.84–1.97 | M: 0.84; I: 1.50 | No | Increased risk in a few studies | Insufficient evidence | Small increase in risk, no evidence of exposure–response, no adjustment for potential confounders | – |
| Leukemia | M: 0.57–1.56; I: 0.28–2.00 | M: 0.84–1.56; I: 0.89–2.00 | Yes: M(1) | Increased risk in a few studies | Insufficient evidence | Small to moderate increase in risk, no evidence of exposure–response, no adjustment for potential confounders | ± |
| Lymphatic and hemopoietic cancers | M: 0.84–2.30; I: 0.85–1.14 | M: 1.01–1.16; I: 0.85–1.13 | Yes: M(2) | Increased risk in a few studies | Insufficient evidence | Small increase in risk, little evidence of exposure–response, no adjustment for potential confounders | ± |
* Bradford-Hill's criteria of specificity and of analogy have not been retained here.
†Studies that have accumulated 100,000 person-years of observation or more are those of Mur et al47 (mortality); Romundstad et al74 (incidence); Spinelli et al40 (incidence and mortality); Gibbs et al43,44,60 (incidence and mortality).
‡Number of studies between parentheses.
§Risk qualification: decreased, less than 1.0; small, 1.1 to 1.5; moderate, 1.6 to 2.0; high, 2.1 or more.
‖Force of evidence categories and criteria: ? (insufficient data), there were few reports concerning these cancer sites that were also rare; − (no convincing evidence), most studies did not show an increased or decreased risk or were studies with a small increased risk that was not statistically significant or were without adjustment for major potential confounders, and/or were studies with some evidence that there was no exposure–response relationship; ± (little evidence), the evidence was deemed insufficient to conclude that there was a possible association, for example, no more than one study with a statistically significant increase in risk or with a risk of more than 1.5, and some inconsistent borderline evidence of exposure–response relationship; + (some evidence), there were a few positive studies showing a possible association with more than one study with a statistically significant increase in risk and more than one study with risk of more than 1.5, and at least borderline evidence of exposure–response in two studies or more; ++ (consistent evidence), the evidence suggested a probable association as most studies showed increased risks with some evidence of exposure–response and at least one study with risk of more than 2.0; +++ (reasonably strong evidence), most studies showed an increased risk with evidence of exposure–response in several studies and more than one study with a risk of more than 2.0.
¶Evidence classified sufficient for humans according to the IARC for this cancer site.
B(a)P, benzo(a)pyrene; EG, exposure gradient; I, incidence; M, mortality; NA, not available; PAHs, polycyclic aromatic hydrocarbons; SS, statistically significant.